BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanner J, Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest. 1991;88:239-247. [PMID: 1647416 DOI: 10.1172/jci115283] [Cited by in Crossref: 61] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol. 2005;79:13993-14003. [PMID: 16254335 DOI: 10.1128/jvi.79.22.13993-14003.2005] [Cited by in Crossref: 155] [Cited by in F6Publishing: 95] [Article Influence: 10.3] [Reference Citation Analysis]
2 Jones K, Rivera C, Sgadari C, Franklin J, Max EE, Bhatia K, Tosato G. Infection of human endothelial cells with Epstein-Barr virus. J Exp Med 1995;182:1213-21. [PMID: 7595192 DOI: 10.1084/jem.182.5.1213] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 1.9] [Reference Citation Analysis]
3 Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, Jewett A. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer 2017;8:537-54. [PMID: 28367234 DOI: 10.7150/jca.15989] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
4 Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, Mencarini J, Caporale R, Peruzzi B, Antonelli A, Trotta M, Zammarchi L, Ciani L, Gori L, Lazzeri C, Matucci A, Vultaggio A, Rossi O, Almerigogna F, Parronchi P, Fontanari P, Lavorini F, Peris A, Rossolini GM, Bartoloni A, Romagnani S, Liotta F, Annunziato F, Cosmi L. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130:4694-4703. [PMID: 32463803 DOI: 10.1172/jci138554] [Cited by in Crossref: 166] [Cited by in F6Publishing: 107] [Article Influence: 166.0] [Reference Citation Analysis]
5 Gomez-Lopez N, Olson DM, Robertson SA. Interleukin-6 controls uterine Th9 cells and CD8(+) T regulatory cells to accelerate parturition in mice. Immunol Cell Biol 2016;94:79-89. [PMID: 26073576 DOI: 10.1038/icb.2015.63] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
6 Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, Rovelli F. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 1999;80:407-11. [PMID: 10408846 DOI: 10.1038/sj.bjc.6690371] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
7 Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013;8:e76781. [PMID: 24204673 DOI: 10.1371/journal.pone.0076781] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 13.6] [Reference Citation Analysis]
8 Simpson WG, Heys SD, Whiting PH, Eremin O, Broom J. Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 1995;99:143-7. [PMID: 7531626 DOI: 10.1111/j.1365-2249.1995.tb05524.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
9 O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol 1998;20:455-91. [PMID: 9870257 DOI: 10.1007/BF00838055] [Cited by in Crossref: 35] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
10 Sarawar SR, Cardin RD, Brooks JW, Mehrpooya M, Tripp RA, Doherty PC. Cytokine production in the immune response to murine gammaherpesvirus 68. J Virol 1996;70:3264-8. [PMID: 8627809 DOI: 10.1128/JVI.70.5.3264-3268.1996] [Cited by in Crossref: 58] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
11 Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993;91:2806-14. [PMID: 8514888 DOI: 10.1172/JCI116523] [Cited by in Crossref: 77] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
12 Wang LS, Chow KC, Wu CW. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 1999;80:1617-22. [PMID: 10408408 DOI: 10.1038/sj.bjc.6690571] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
13 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12:2563-2568. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16] [Reference Citation Analysis]
14 . L'inflammation dans la Mucoviscidose. Mediators Inflamm 1996;5:144-69. [PMID: 18475711 DOI: 10.1155/S0962935196000221] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Bussu F, Graziani C, Gallus R, Cittadini A, Galli J, DE Corso E, DI Cintio G, Corbi M, Almadori G, Boninsegna A, Paludetti G, Sgambato A. IFN-γ and other serum cytokines in head and neck squamous cell carcinomas. Acta Otorhinolaryngol Ital 2018;38:94-102. [PMID: 29967556 DOI: 10.14639/0392-100X-1530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
16 Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, Polverini PJ, Kenney SC. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005;79:13984-92. [PMID: 16254334 DOI: 10.1128/JVI.79.22.13984-13992.2005] [Cited by in Crossref: 76] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
17 Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 2009;54:683-689. [PMID: 18661238 DOI: 10.1007/s10620-008-0390-z] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
18 Oduor CI, Chelimo K, Ouma C, Mulama DH, Foley J, Vulule J, Bailey JA, Moormann AM. Interleukin-6 and interleukin-10 gene promoter polymorphisms and risk of endemic Burkitt lymphoma. Am J Trop Med Hyg 2014;91:649-54. [PMID: 25071000 DOI: 10.4269/ajtmh.13-0616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Tanner JE, Alfieri C, Chatila TA, Diaz-Mitoma F. Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220. J Virol 1996;70:570-5. [PMID: 8523572 DOI: 10.1128/JVI.70.1.570-575.1996] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
20 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563-8. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16.2563] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 67] [Article Influence: 4.3] [Reference Citation Analysis]
21 Calkoen FG, Vervat C, Eising E, Vijfhuizen LS, 't Hoen PB, van den Heuvel-Eibrink MM, Egeler RM, van Tol MJ, Ball LM. Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia. Haematologica 2015;100:1434-41. [PMID: 26294732 DOI: 10.3324/haematol.2015.126938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Crestani B, Cornillet P, Dehoux M, Rolland C, Guenounou M, Aubier M. Alveolar type II epithelial cells produce interleukin-6 in vitro and in vivo. Regulation by alveolar macrophage secretory products. J Clin Invest 1994;94:731-40. [PMID: 8040328 DOI: 10.1172/JCI117392] [Cited by in Crossref: 112] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
23 Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995;71:1095-1098. [PMID: 7734307 DOI: 10.1038/bjc.1995.212] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 4.7] [Reference Citation Analysis]
24 Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:354-356. [PMID: 7841052 DOI: 10.1038/bjc.1995.71] [Cited by in Crossref: 140] [Cited by in F6Publishing: 128] [Article Influence: 5.4] [Reference Citation Analysis]